| 27.35 0.64 (2.4%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.7 | 1-year : | 38.19 |
| Resists | First : | 28 | Second : | 32.7 |
| Pivot price | 24.98  |
|||
| Supports | First : | 24.55 | Second : | 22.43 |
| MAs | MA(5) : | 26.34 |
MA(20) : | 24.6 |
| MA(100) : | 24.38 |
MA(250) : | 18.29 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 91.2 |
D(3) : | 84.5 |
| RSI | RSI(14): 68.9 |
|||
| 52-week | High : | 28.48 | Low : | 9.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZYME ] has closed Bollinger Bands are 14.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.45 - 27.54 | 27.54 - 27.63 |
| Low: | 25.8 - 25.92 | 25.92 - 26.03 |
| Close: | 27.15 - 27.33 | 27.33 - 27.48 |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Thu, 09 Apr 2026
Zymeworks Bolsters Executive Team to Drive Next Phase of Growth - TipRanks
Thu, 09 Apr 2026
Zymeworks makes two interim leaders permanent to steer pipeline and deals - Stock Titan
Wed, 08 Apr 2026
Why Zymeworks (ZYME) Is Up 6.7% After FDA Fast Track Win And CFO Appointment - Sahm
Tue, 07 Apr 2026
Zymeworks (NASDAQ: ZYME) CFO reports zero beneficial share ownership - Stock Titan
Mon, 06 Apr 2026
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME - MarketBeat
Mon, 06 Apr 2026
A Look At Zymeworks (ZYME) Valuation After Fast Track Win And New CFO Appointment - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 74 (M) |
| Held by Insiders | 7.277e+007 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 3,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.482e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -76.6 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 755.5 % |
| Return on Equity (ttm) | -14.3 % |
| Qtrly Rev. Growth | 1.0597e+008 % |
| Gross Profit (p.s.) | -71.8 |
| Sales Per Share | -20.88 |
| EBITDA (p.s.) | -2.425e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.32 |
| Price to Cash Flow | 9.72 |
| Dividend | 0 |
| Forward Dividend | 4.08e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|